Pfizer: Stroke trials
The registry lists 12 Stroke studies with Pfizer as lead sponsor. 0 are open to participants now and 6 have results posted.
Phase 2 1Phase 3 2Phase 4 2No phase 7(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Safety and Effectiveness of Apixaban in Very Elderly Patients With Non-valvular Atrial Fibrillation (NVAF) Compared to Warfarin Using Administrative Claims DataCompletedNCT05438888Results posted
- Safety and Effectiveness of Apixaban Compared to Warfarin in Secondary Prevention in Patients With Atrial FibrillationCompletedNCT05321810Results posted
- Effectiveness And Safety Of Oral Anticoagulants Among Obese Patients With Non-Valvular A-Fib In VA Patients With MedicareCompletedNCT04681482Results posted
- Apixaban Drug Utilization Study In Stroke Prevention In Atrial Fibrillation (Spaf)CompletedNCT03441633Results posted
- The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk SubjectsTerminatedNCT01975389Phase 3Results posted
- The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk SubjectsTerminatedNCT01975376Phase 3Results posted
- High Gastrointestinal Bleed Risk Outcomes in Patients With Non-valvular Atrial Fibrillation (NVAF) in FranceCompletedNCT05038228
- NOAC Portuguese Real World StudyWithdrawnNCT04808934
- A Study of Adverse Events and Suspected Adverse Drug Reactions in Patients Under Apixaban for Prevention of Stroke and Systemic Embolism With Non-Valvular Atrial Fibrillation and Venous Thromboembolic Events in Patients Who Have Undergone Elective Hip or Knee Replacement SurgeryWithdrawnNCT03804125
- A Study to Determine the Degree of Additional Reduction in CV Risk in Lowering LDL Below Minimum Target LevelsCompletedNCT00327691Phase 4
- CARDS Is Designed To Show If Lowering Cholesterol With Atorvastatin In Type 2 Diabetics Without CV Disease Reduces The Risk Of CV EventsCompletedNCT00327418Phase 4
- A Study to Evaluate the Efficacy and Safety of CP-101,606 in Subjects With an Acute StrokeTerminatedNCT00073476Phase 2